Search results for ""
| Status | Drug name | NICE TAs | Comments | Subchapter |
|---|---|---|---|---|
 |
Co-careldopa M/R tablets | 4.9 | ||
|
Co-careldopa tablets | 4.9 | ||
 |
Co-codamol 30/500 capsules | Wherever possible, avoid theu se of combination products. Use paracetamol and codeine separately. All combination products of paracetamol and codeine/dihydrocodeine are deemed products less suitable for prescribing in the BNF. Capsules have a very high relative cost. Sodium content. Only if swallowing difficulties. |
4.7 | |
|
Co-codamol 30/500 effervescent tablets | Wherever possible, avoid theu se of combination products. Use paracetamol and codeine separately. All combination products of paracetamol and codeine/dihydrocodeine are deemed products less suitable for prescribing in the BNF. Capsules have a very high relative cost. Sodium content. Only if swallowing difficulties. |
4.7 | |
|
Co-codamol 30/500 tablets | Wherever possible, avoid theu se of combination products. Use paracetamol and codeine separately. All combination products of paracetamol and codeine/dihydrocodeine are deemed products less suitable for prescribing in the BNF. Capsules have a very high relative cost. Sodium content. Only if swallowing difficulties. |
4.7 | |
 |
Coconut oil 25% w/w in emulsifying ointment | Unlicensed special |
13.14 | |
|
Co-Cyprindiol 2000/35 | 13.6 | ||
|
Co-danthramer capsules | For terminally ill patients |
1.6 | |
|
Co-danthramer suspension | For terminally ill patients |
1.6 | |
|
Co-danthrusate capsules | For terminally ill patients |
1.6 |
- First page
- Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
- 175
- 176
- 177
- 178
- 179
- 180
- 181
- 182
- 183
- 184
- 185
- 186
- 187
- 188
- 189
- 190
- 191
- 192
- 193
- 194
- 195
- 196
- 197
- 198
- 199
- 200
- 201
- 202
- 203
- 204
- 205
- 206
- Next page
- Last page
Drug status key
Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.
Grey
Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.
Red
Initiation and maintenance of prescribing by specialists only.
Amber
Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.
Green
Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.
Blue
Under review at University Hospitals Birmingham NHS Foundation Trust.
